MetroCity Bankshares (MCBS) increases quarterly cash dividend to $0.23/share

MetroCity Bankshares increases quarterly cash dividend to $0.23/share from $0.20/share and announces the continuation of its share repurchase program 

• The Company approves the continuation of its share repurchase program that expired on September 30, 2024 and authorized the Company to repurchase up to 925,250 shares of the Company's outstanding shares of common stock, which is the number of remaining shares authorized for repurchase from the Prior Share Repurchase Plan.
• The share repurchase program will begin on October 17, 2024 and end on September 30, 2025.

Earnings Date	Oct 18, 2024
Forward Dividend & Yield	0.80 (2.58%)
Ex-Dividend Date	Jul 31, 2024

Dividend Payable Date    Aug 9, 2024

X: Oct 10, vol. 17K

 

 

 

Fulcrum Therapeutics (FULC) : Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

― Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 

― Fulcrum to suspend future losmapimod development 

― Robust cash position enables Fulcrum to continue its mission to develop therapies addressing diseases of high unmet need including pociredir for the treatment of sickle cell disease (SCD)

 

 

 

 

 

 

 

Fulcrum Therapeutics is a biopharmaceutical company that focuses on developing small molecule therapies to treat rare diseases. The company was founded in Cambridge, Massachusetts in July 2016 by Third Rock Ventures.
It went public on July 17, 2019.

About the REACH Trial
REACH (NCT05397470) is a Phase 3 multi-center, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of losmapimod for the treatment of FSHD. The trial enrolled 260 patients who were randomized 1:1 to receive either losmapimod, administered orally as a 15 mg tablet twice a day, or placebo over a 48-week treatment period. The primary endpoint was the absolute change from baseline in Reachable Workspace (RWS). Secondary endpoint measurements included Muscle Fat Infiltration (MFI) as measured by MRI, shoulder abductor strength as measured by hand-held dynamometry, Patient Global Impression of Change (PGIC), and the Neuro QoL Upper Extremity.

About FSHD
FSHD is a serious, rare, progressive and debilitating disease for which there are no approved treatments. It is characterized by fat infiltration of skeletal muscle leading to muscular atrophy involving primarily the face, scapula and shoulders, upper arms, and abdomen. Impact on patients includes relentless and accumulating muscle and functional loss impacting their ability to perform activities of daily living, loss of upper limb function, loss of mobility and independence, and chronic pain. FSHD is one of the most common forms of muscular dystrophy and has an estimated patient population of 30,000 in the United States alone.

Mereo BioPharma (MREO) : 5-year performance

• Mereo BioPharma (MREO) was founded in March 2015 to fund and develop high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies.
• It acquired a portfolio of three product candidates from Novartis in July 2015 and a fourth product from AstraZeneca in October 2017. In April 2019, Mereo merged with OncoMed, a Nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing novel oncology products.
• OncoMed Pharmaceuticals (OMED) had its IPO on Jul 17, 2013. The company sold 4.8 million shares at $17, above the $14 to $16 shares range laid out earlier. The offering raised $82 million.

Fiverr International (FVRR) : 5-year performance

 ticker: FVRR

Precision BioSciences (DTIL) : 5-year performance

ticker: DTIL

 

Cambium Networks (CMBM) : 5-year performance

ticker: CMBM

Zymeworks (ZYME) : 5-year performance

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 455
• incorporated in 2003 
• HQ: Vancouver, Canada.
• https://www.zymeworks.com

First day of trading Friday April 28, 2017

Vancouver, British Columbia-based biotherapeutics provider Zymeworks Inc has raised $58.5 million for its IPO after pricing its 4.5 million shares at $13 per share. The stock began trading April 28, 2017 on the New York Stock Exchange and on the Toronto Stock Exchange under the ticker symbol “ZYME";

Citigroup Global Markets Canada Inc., Barclays Capital Inc. and Wells Fargo Securities, LLC are the lead underwriters. Zymeworks'  pre-IPO backers include BDC Capital, Lumira Capital, CTI Life Sciences Fund, Fonds de solidarité FTQ, Perceptive Advisors, Teralys Capital, Northleaf Venture Catalyst Fund, Brace Pharma Capital and Merlin Nexus.

Catabasis Pharmaceuticals (CATB) : 5-year performance

 

Aimmune Therapeutics (AIMT) to be acquired by Nestle (NSRGY) for $34.50 per share

• Following years of increasing its financial position in California-based Aimmune, Sociétés des Produits Nestlé, S.A., a part of Nestlé Health Science, acquired the outstanding shares of the food allergy-focused company for $2.6 billion in cash.
• Aimmune, which won regulatory approval in February for Palforzia, a first-of-its-kind treatment for patients with peanut allergies. Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] is an oral treatment indicated to mitigate allergic reactions to peanuts.

 

Aimmune Therapeutics to be acquired by unit of Nestle Health Science (NSRGY) for $34.50 per share

Aimmune Therapeutics, a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, announced that it has entered into a definitive agreement for Socits des Produits Nestl, S.A. to acquire Aimmune for $34.50 per share in an all-cash transaction, implying a fully-diluted equity value of $2.6 bln. Socits des Produits Nestl, S.A. is a part of Nestl Health Science (NHSc) and a wholly owned subsidiary of Nestl S.A.

Under the terms of the merger agreement, Nestl S.A.'s wholly-owned subsidiary Socit des Produits Nestl S.A. (SPN) will commence a cash tender offer to acquire all outstanding shares of Aimmune common stock that are not already owned by NHSc for $34.50 per share in cash, and Aimmune agreed to file a recommendation statement containing the unanimous recommendation of the independent members of the Aimmune board that Aimmune stockholders tender their shares to SPN.

• Following the completion of the tender offer, Nestl expects to promptly consummate a merger of Aimmune with a subsidiary of SPN, in which shares of Aimmune that have not been tendered in the tender offer will be acquired by SPN and converted into the right to receive the same cash price per share as paid in the tender offer.

OnDeck Capital (ONDK) to be acquired by Enova International (ENVA) for $90 million

• Enova, the online lender for consumers and small businesses, is paying a 90% premium to OnDeck’s Monday’s closing stock price of $0.73 a share in the stock and cash deal. Combined the two companies had $4.7 billion in originations last year and have served more than 7 million customers.

 

** ONDK charts 2 months earlier 5/21/20 ** 

daily

monthly

Adaptimmune Therapeutics (ADAP) : positive data on experimental cell therapy

• The company said that trials of its SPEAR T-cell therapy showed a 50% response rate in patients with synovial sarcoma. The company also reported confirmed responses in lung cancer patients, and had previously reported confirmed responses in head and neck cancer patients. 

 

Adaptimmune Therapeutics presented updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology Annual Meeting

New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy.

Durability and efficacy data presented at ASCO support potential for SPEARHEAD-1 as a registrational trial for sarcoma - commercial launch planned in the US in 2022.

Phase 2 trial combining ADP-A2M4 with pembrolizumab in head and neck cancer (SPEARHEAD-2) will be the first time a SPEAR T-cell therapy is used in sequence with first line systemic therapy.

The company also announced new responses in the SURPASS trial, confirming the potential for SPEAR T-cell therapies targeting MAGE-A4 to treat a broad range of cancers in addition to sarcoma. These data further support the rationale for two new Phase 2 trials -- SPEARHEAD-2 in head and neck cancer, which will begin later this year, and a second trial in esophagogastric junction (EGJ) cancer planned for 1H 2021.

The SURPASS trial (a Phase 1 trial with ADP-A2M4CD8) will focus on lung, EGJ, head and neck, and bladder cancers.

Confirmed complete response in a patient with liver cancer in the Phase 1 ADP-A2AFP trial (reported as partial response in January).

-=Kura Oncology (KURA) :

Rises to its highest levels since December on above 9x average volume, posting gains alongside its peer in the cancer treatments development space, Syndax Pharmaceuticals (SNDX); co's pipeline includes a menin-MLL inhibitor, KO-539.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 57
• Founded in 2014 
• HQ inSan Diego, California
• http://www.kuraoncology.com

Synchrony Financial (SYF) reported earnings on Fri 24 Jan 20 (b/o)

** charts after earnings **

 

Synchrony Financial beats by $0.03
Reports Q4 (Dec) earnings of $1.10 per share, excluding non-recurring items, $0.03 better than the S&P Capital IQ Consensus of $1.07.

Synchrony Financial provides FY20 outlook in slide presentation

• Co sees FY20 loan receivables growth of +5-7%.
• Co sees FY20 net internet margin of 15.25-15.50%.

QURE, 5-year performance

Enova International (ENVA) : 5-year performance

 

Lending Club (LC) reported earnings on Tue 5 Nov 19 (a/h)

 ** charts after earnings **

 

 

 

Lending Club beats by $0.07, reports revs in-line

Reports Q3 (Sep) earnings of $0.09 per share, excluding non-recurring items, $0.07 better than the S&P Capital IQ Consensus of $0.02; revenues rose 10.9% year/year to $204.9 mln vs the $204.63 mln S&P Capital IQ Consensus.

Loan Originations -- Loan originations in the third quarter of 2019 were $3.3 billion, improving 16% compared to the same quarter last year.

Paylocity (PCTY) reported earnings on Thur 8 Aug 2019 (a/h)

** charts before earnings ** 

 

** charts after earnings **

  

Paylocity beats by $0.09, beats on revs; guides SepQ revs above consensus; guides FY20 revs above consensus

Reports Q4 (Jun) earnings of $0.34 per share, excluding non-recurring items, $0.09 better than the S&P Capital IQ Consensus of $0.25; revenues rose 24.6% year/year to $120.4 mln vs the $117.5 mln S&P Capital IQ Consensus.

Co issues upside guidance for Q1 (Sep), sees Q1 revs of $123.5-124.5 mln vs. $123.0 mln S&P Capital IQ Consensus.

Co issues upside guidance for FY20, sees FY20 revs of $563.5-565.5 mln vs. $562.2 mln S&P Capital IQ Consensus.